HRS-4029

Unknown / undisclosed

Phase 2Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Acute Ischemic Stroke
NCT07739160 · Beijing Suncadia Pharmaceuticals Co., Ltd
2026-09-29 – 2027-07 · Acute Ischemic Stroke
What this study did
Phase 1 (1)
Acute Ischemic Stroke
NCT06905314 · Beijing Suncadia Pharmaceuticals Co., Ltd
2025-04 – 2025-12 · Acute Ischemic Stroke
What this study did

Competitive landscape

This drug's own stage for Acute Ischemic Stroke: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-4029: this drugPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorReliable signal
NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants
Edaravone (TTYP01)Phase 3Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
Rinvecalinase AlfaPhase 2/3Protein / enzyme therapeuticTissue kallikrein-1 (KLK1)not yet gradedNo reviewed efficacy summary in this indication
Apadamtase Alfa (Adzynma)Phase 2Protein / enzyme therapeuticADAMTS13not yet gradedNo reviewed efficacy summary in this indication
HRS-7450Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-8829
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HRS-4029 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 2Acute Ischemic StrokeRecruiting
Est. primary completion 2027-04 · NCT07739160 · CT.gov ↗
What to watch

See the full readout calendar ↗